KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Supernus Pharmaceuticals (SUPN) Other Gross PP&E Adjustments: 2011-2025

Historic Other Gross PP&E Adjustments for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to -$13.5 million.

  • Supernus Pharmaceuticals' Other Gross PP&E Adjustments fell 172.45% to -$13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year decrease of 135.48%. This contributed to the annual value of -$6.1 million for FY2024, which is 48.01% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Other Gross PP&E Adjustments of -$13.5 million as of Q3 2025, which was down 73.39% from -$7.8 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Other Gross PP&E Adjustments registered a high of $25.4 million during Q1 2021, and its lowest value of -$36.4 million during Q2 2022.
  • In the last 3 years, Supernus Pharmaceuticals' Other Gross PP&E Adjustments had a median value of $12.5 million in 2023 and averaged $5.9 million.
  • Data for Supernus Pharmaceuticals' Other Gross PP&E Adjustments shows a peak YoY increase of 173.46% (in 2021) and a maximum YoY decrease of 251.54% (in 2021) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Gross PP&E Adjustments (Quarterly) stood at -$28.7 million in 2021, then skyrocketed by 39.11% to -$17.5 million in 2022, then surged by 32.87% to -$11.7 million in 2023, then skyrocketed by 48.01% to -$6.1 million in 2024, then plummeted by 172.45% to -$13.5 million in 2025.
  • Its Other Gross PP&E Adjustments stands at -$13.5 million for Q3 2025, versus -$7.8 million for Q2 2025 and $14.9 million for Q1 2025.